Under a collaboration with the NFL Players Association, over 400 former players have had brain-body health evaluations at Cleveland Clinic to get a sense of the brain health path they appear to be on. Here’s how it works.
The year’s notable brain health developments include results from the BEAT-AD trial of bexarotene for Alzheimer’s disease and the launch of DIAGNOSE CTE for in vivo detection of chronic traumatic encephalopathy.
A recent report estimated that 35.6 million people worldwide lived with dementia in 2010. By the year 2030 this is expected to double. A Cleveland Clinic functional medicine nutritionist says healthcare providers can help patients understand the connection between cognitive function and diet.
An expert panel at Cleveland Clinic’s recent Medical Innovation Summit explained why much earlier intervention will be key to success in AD therapeutics — and how biomarkers and big data will help us get there.
The Lou Ruvo Center for Brain Health is working to transform the clinical trial process for Alzheimer disease. It is committed to focusing on the right patients, the right drugs and the right outcomes.
Alzheimer disease, Parkinson disease, normal aging and neuroinflammation are priority focus areas of the biobank, which aim to promote identification of novel biomarkers. The facility will benefit from Cleveland Clinic’s large, diverse patient population and neuroinflammation research expertise.
A breakthrough in the quest for a disease-modifying AD therapy is long overdue. Cleveland Clinic has developed a large, diverse and multisite clinical trials program in response. Here’s what drives our approach.
No research until now has combined imaging, behavioral assessment and impact-dynamic studies to begin to pinpoint the dose of head impact needed to produce acute brain changes linked to neurodegenerative disease.
The FDA-approved lymphoma therapy bexarotene reduces brain amyloid in a mouse model of Alzheimer disease (AD). The BEAT-AD study is now studying it for the first time in humans with AD.
Even with an estimated 44 million people living with Alzheimer s disease (AD), relatively few new AD drugs are in development. Additionally, the failure rate for AD drug development is 99.6 percent from the years 2002 to 2012 and the number of AD drugs has been declining since 2009. In a new analysis published today, researchers say there is an urgent need to increase the number of agents entering the AD drug development pipeline.